BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23398206)

  • 41. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Highly increased risk of fracture in patients with myeloproliferative neoplasm.
    Johansson P; Kristjansdottir HL; Johansson H; Jakir A; Mellström D; Lewerin C
    Leuk Lymphoma; 2021 Jan; 62(1):211-217. PubMed ID: 32909485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
    Grunwald MR; Burke JM; Kuter DJ; Gerds AT; Stein B; Walshauser MA; Parasuraman S; Colucci P; Paranagama D; Savona MR; Mesa R
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):579-584.e1. PubMed ID: 31303457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality of life in MPN comes of age as a therapeutic target.
    Scherber RM; Geyer HL; Mesa RA
    Curr Hematol Malig Rep; 2014 Dec; 9(4):324-30. PubMed ID: 25262210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic myeloproliferative diseases.
    de Lacerda JF; Oliveira SN; Ferro JM
    Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
    Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
    Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications.
    Šefer D; Bižić-Radulović S; Kraguljac-Kurtović N; Bogdanović A; Čokić V; Miljić P; Beleslin-Čokić B; Knežević V; Mitrović-Ajtić O; Leković D; Gotić M
    Int J Lab Hematol; 2017 Feb; 39(1):21-31. PubMed ID: 28025866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
    Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
    Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms.
    McFarland DC; Polizzi H; Mascarenhas J; Kremyanskaya M; Holland J; Hoffman R
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1563-1570. PubMed ID: 27956541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Yigit N; Covey S; Barouk-Fox S; Turker T; Geyer JT; Orazi A
    Hum Pathol; 2015 Aug; 46(8):1217-25. PubMed ID: 26093937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessing disease burden in patients with classic MPNs.
    Geyer H; Mesa RA
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
    Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
    Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
    Ochiai T; Yasuda H; Araki M; Misawa K; Morishita S; Nudejima M; Hironaka Y; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Eur J Haematol; 2018 Jun; 100(6):544-549. PubMed ID: 29405428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Melancholia and the myeloproliferative syndrome. Apropos of a case].
    Delandsheer E; Destee A; Warot P
    Lille Med; 1980; 25(1-2):15-7. PubMed ID: 7374330
    [No Abstract]   [Full Text] [Related]  

  • 60. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
    Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
    Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.